Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2022-10-21 Interim / Quarterly Rep…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at 30.09.2022' and contains comprehensive financial information, including consolidated interim financial statements, explanatory notes, and a report of the statutory auditors. It covers a period shorter than a full fiscal year (nine months ending September 30, 2022). It is not a short announcement or a certification, but a full interim financial report. 9M 2022
2022-10-21 English
Edison issues review on BB Biotech (BION)
Regulatory Filings Classification · 98% confidence The document is a short announcement (4697 characters) distributed via RNS, specifically mentioning it is provided by 'Reach, the non-regulatory press release distribution service of RNS'. The content is an 'Edison issues review on BB Biotech (BION)' and includes a link to view the 'full report'. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement that points to a full report, especially one distributed via a non-regulatory channel like Reach, should be classified as a Report Publication Announcement (RPA) rather than the report itself (like IP or FS). Since it explicitly announces the publication of a research report by Edison, RPA is the most appropriate classification.
2022-09-14 English
BB BIOTECH AG: Moderna was just the beginning
Regulatory Filings Classification · 95% confidence The document is dated August 30, 2022, and is titled 'BB BIOTECH AG: Moderna was just the beginning'. It contains market commentary from the Head of Investment Management Team, discussing portfolio performance, specific stock movements (Alnylam), and broader industry trends (RNA technology). It is explicitly marked as 'DGAP-News' and discusses investment insights rather than presenting audited financial statements (10-K, AR, IR) or official voting results (DVA). It is a commentary piece on market activity and investment strategy, which aligns best with a general Investor Relations/Market Report type of communication. Since there is no specific category for 'Market Commentary' or 'Investment Update' that isn't a formal presentation (IP) or earnings release (ER), and it is a news item disseminated via DGAP, it falls under the general Regulatory Filings (RNS) category, which serves as a fallback for general corporate news releases not covered by more specific codes like DIV, CAP, or ER. Given the content is an analysis/commentary rather than a formal statutory report, RNS is the most appropriate fit among the provided options.
2022-08-30 English
DGAP-News: BB BIOTECH AG: Moderna è stata solo l’inizio
Regulatory Filings Classification · 95% confidence The document is titled 'DGAP-News: BB BIOTECH AG / Parola (s): Bollettino di mercato' and contains commentary from an investment team member regarding portfolio companies (Alnylam, Moderna, Ionis) and market trends in biotechnology, specifically RNA-based therapies. It discusses clinical trial results, market expectations, and the company's investment strategy. This format—a market commentary or analysis piece released via a news service (DGAP)—is characteristic of an Investor Presentation (IP) or a detailed market update, rather than a formal regulatory filing like a 10-K, ER, or IR. Given the depth of analysis and forward-looking statements focused on investment theses, 'Investor Presentation' (IP) is the most fitting category, as it functions as a detailed update for investors, even if presented as a 'Bollettino di mercato' (Market Bulletin). It is not a formal earnings release (ER) or a quarterly report (IR) as it focuses on investment commentary rather than mandated financial statements.
2022-08-30 Italian
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
Regulatory Filings Classification · 99% confidence The document is titled 'DGAP-News: BB BIOTECH AG / Key word(s): Market Report' and contains a 'Market commentary, August 30, 2022' authored by the Head Investment Management Team. It discusses portfolio company performance (Alnylam, Moderna, Ionis) and market trends in RNA-based drugs. This content is characteristic of an investment update or market commentary provided by an investment firm (BB Biotech) to its stakeholders, often released via regulatory news services (indicated by DGAP). Since it is not a formal financial statement (10-K, IR, ER, MRQ) nor a presentation (IP, AGM-R), and it is a commentary/update, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for regulatory news announcements that don't fit specific financial reporting codes. It is too detailed and substantive to be a simple Report Publication Announcement (RPA).
2022-08-30 English
DGAP-News: BB BIOTECH AG: Moderna war erst der Anfang
Management Reports Classification · 99% confidence The document is titled 'DGAP-News: BB BIOTECH AG / Schlagwort(e): Marktbericht' and contains a 'Marktkommentar' (Market Commentary) dated 30.08.2022, authored by the Head of Investment Management. It discusses portfolio company performance (Alnylam, Moderna, Ionis) and the outlook for RNA-based therapies. This content is analytical and forward-looking commentary provided by management/investment professionals regarding market trends and portfolio holdings, rather than a formal regulatory filing (like 10-K, IR, or ER) or a simple announcement of a report (RPA/RNS). It fits best under the category of Investor Presentation (IP) or potentially Management Reports (MDA), but given its structure as a detailed market commentary piece intended for investors, 'Investor Presentation' (IP) is the most appropriate fit, as it serves a similar informational purpose to an investor presentation deck, even if delivered as text commentary. It is not a formal Earnings Release (ER) or Interim Report (IR) as it focuses on investment strategy and specific stock movements rather than comprehensive period financials.
2022-08-30 German

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.